Zevra Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Zevra Therapeutics Inc.
Former names: Kempharm, Inc
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Boston
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: ZVRA
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001434647
EIN: 20-5894398

Board of directors

Follow this board

Alicia Secor · Director
Since 2025
Alvin Shih · Director
Since 2024
Corey Michael Watton · Director
Since 2023
David S. Tierney · Director
Since 2023
Douglas W. Calder · Director
Since 2023
John B. Bode · Director
Since 2023
Joseph Saluri · Director
Since 2023
Matthew R. Plooster · Director
Since 2023
Neil F. McFarlane · Director · President and CEO
Since 2023
Richard W. Pascoe · Director · Chief Executive Officer
Since 2023
Tamara A. Seymour · Director
Since 2023
Thomas Anderson · Director
Since 2023
Wendy L. Dixon · Director
Since 2023

Chief executives

Neil F. McFarlane · President and CEO

Since October 2023

100 CEO score

Outstanding · grade A+

Out of 100, from shareholder return, dividends, growth and acquisitions.

Partial: only 20% of the scoring weight is on file.

Revenue growth 20%: 100

20% of the scoring weight is on file. Figures cover December 2022 – December 2025.

Richard W. Pascoe · Chief Executive Officer

Until October 2023 · Former

Director election results

Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Douglas W. Calder

76.4%
Corey Michael Watton

88.6%

Board connections

6 of this board's directors also sit on 9 other boards. 6 are in the same sector.

Shared director Other board Same sector

Artelo Biosciences Inc. Same sector
via Tamara A. Seymour
Arvinas Inc. Same sector
via Wendy L. Dixon
Black Diamond Therapeutics Inc. Same sector
via Wendy L. Dixon
Collegium Pharmaceutical Inc. Same sector
via Neil F. McFarlane
Lunai Bioworks Inc. Same sector
via Douglas W. Calder
Newton Golf Company Inc.
via John B. Bode
Oaktree Acquisition Corp. III Life Sciences
via Alvin Shih
Stewards Inc
via John B. Bode
TuHURA Biosciences Inc. Same sector
via Tamara A. Seymour

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $2,520,745; 13 sales by 6 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 12, 2026	Neil F. McFarlane Director, Officer (President and CEO)	Open-market sale	−20,000	$11.25	$224,948
Oct 10, 2026	Neil F. McFarlane Director, Officer (President and CEO)	Option exercise	+50,000	—	—
Aug 14, 2026	Thompson Rahsaan Officer (Chief Legal & Compliance)	Open-market sale	−42,666	$11.13	$474,873
Aug 10, 2026	Corey Michael Watton Director	Option exercise	+12,300	$4.97	$61,131
Aug 10, 2026	Corey Michael Watton Director	Open-market sale	−12,300	$11.25	$138,375
Jun 22, 2026	Thompson Rahsaan Officer (Chief Legal & Compliance)	Open-market sale	−34,557	$12.68	$438,183
Jun 21, 2026	Thompson Rahsaan Officer (Chief Legal & Compliance)	Option exercise	+66,667	—	—
May 11, 2026	Thompson Rahsaan Officer (Chief Legal & Compliance)	Open-market sale	−1,794	$11.30	$20,272
Mar 24, 2026	John B. Bode Director	Option exercise	+39,200	$4.97	$194,824
Mar 24, 2026	John B. Bode Director	Option exercise	+39,200	$4.89	$191,688
Feb 9, 2026	Neil F. McFarlane Director, Officer (President and CEO)	Open-market sale	−14,625	$8.56	$125,190
Feb 7, 2026	Neil F. McFarlane Director, Officer (President and CEO)	Option exercise	+37,500	—	—
Feb 3, 2026	Sangiovanni Timothy J. Officer (SVP, Finance & Corp Controller)	Open-market sale	−3,000	$9.18	$27,540
Feb 3, 2026	Joshua Schafer Officer (CCO)	Open-market sale	−10,500	$9.19	$96,495
Feb 2, 2026	Neil F. McFarlane Director, Officer (President and CEO)	Open-market sale	−91,000	$9.38	$853,580

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Zevra Therapeutics Inc.

Who is the CEO of Zevra Therapeutics Inc.?

Neil F. McFarlane has been Zevra Therapeutics Inc.'s President and CEO since October 2023.

How many directors are on Zevra Therapeutics Inc.'s board?

Zevra Therapeutics Inc.'s board has 13 directors: Alicia Secor, Alvin Shih, Corey Michael Watton, David S. Tierney, Douglas W. Calder, John B. Bode, Joseph Saluri, Matthew R. Plooster, Neil F. McFarlane, Richard W. Pascoe and 3 others.

Are Zevra Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Zevra Therapeutics Inc. insiders made no open-market purchases and sold $2.5 million of shares in 13 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Zevra Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="zevra-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.